Prevention and Management of Dermatologic Adverse Events in Patients Treated with Amivantamab Plus Lazertinib
Open Access
- 4 February 2026
- journal article
- case report
- Published by MDPI AG in Current Oncology
- Vol. 33 (2) , 96
Abstract
Amivantamab plus lazertinib (amivantamab+lazertinib) is a novel combination therapy used to treat epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). Although this regimen has demonstrated clinical efficacy in locally advanced or metastatic NSCLC, it is associated with a range of dermatologic adverse events that may develop rapidly and require prompt intervention. Early management of these side effects is critical for maintaining oncologic treatment, optimizing clinical outcomes, and improving patients’ quality of life. Cases: We present four patients with EGFR-mutated NSCLC who experienced dermatologic adverse events during amivantamab+lazertinib therapy. Two developed severe facial papulopustular eruptions, and two presented with necrotic folliculitis with sanguineous scalp erosions. Additional dermatologic manifestations included paronychia, pruritus, xerosis, mucositis, and trichomegaly. Notably, one patient experienced milder dermatologic side effects due to early initiation of a dermatologic prophylactic regimen. Conclusions: Dermatologic adverse events during amivantamab+lazertinib therapy are frequent and may be more severe than those typically observed with EGFR inhibitors. Early prophylactic measures and timely intervention are essential for managing these adverse events, supporting treatment adherence, and maximizing the therapeutic efficacy of this combined oncologic regimen.Keywords
This publication has 21 references indexed in Scilit:
- P3.12D.04 Enhanced vs Standard Dermatologic Management with Amivantamab-Lazertinib in Advanced NSCLC: Phase 2 COCOON StudyJournal of Thoracic Oncology, 2024
- Erosive pustular dermatosis-like eruption of the scalp secondary to amivantamab: A case seriesJAAD Case Reports, 2024
- The role of dermocosmetics in the management of cancer-related skin toxicities: international expert consensusSupportive Care in Cancer, 2023
- Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trialNature Medicine, 2023
- Spectrum of Dermatologic Adverse Events Associated With Amivantamab UseJAMA Dermatology, 2023
- The extent to which the last decade has yielded additional treatment options for EGFR-associated rash besides classic treatment with antibiotics and corticosteroids - A systematic reviewEuropean Journal of Oncology Nursing, 2021
- Erosive pustular dermatosis of the scalp: A neutrophilic folliculitis within the spectrum of neutrophilic dermatosesJournal of the American Academy of Dermatology, 2019
- Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and NailsAmerican Journal of Clinical Dermatology, 2018
- EGFR inhibitor-induced skin reactions: differentiating acneiform rash from superimposed bacterial infectionsSupportive Care in Cancer, 2016
- Mechanisms of cutaneous toxicities to EGFR inhibitorsNature Reviews Cancer, 2006